[go: up one dir, main page]

TN2012000157A1 - Treatment using reprogrammed mature adult cells - Google Patents

Treatment using reprogrammed mature adult cells

Info

Publication number
TN2012000157A1
TN2012000157A1 TNP2012000157A TN2012000157A TN2012000157A1 TN 2012000157 A1 TN2012000157 A1 TN 2012000157A1 TN P2012000157 A TNP2012000157 A TN P2012000157A TN 2012000157 A TN2012000157 A TN 2012000157A TN 2012000157 A1 TN2012000157 A1 TN 2012000157A1
Authority
TN
Tunisia
Prior art keywords
cells
patient
retrodifferentiated
transdifferentiated
treatment
Prior art date
Application number
TNP2012000157A
Inventor
Ilham Mohamed Saleh Saeed Abuljadayel
Original Assignee
Tristem Trading (Cyprus) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tristem Trading (Cyprus) Ltd filed Critical Tristem Trading (Cyprus) Ltd
Publication of TN2012000157A1 publication Critical patent/TN2012000157A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)

Abstract

A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.
TNP2012000157A 2009-10-19 2012-04-04 Treatment using reprogrammed mature adult cells TN2012000157A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/051396 WO2011048350A1 (en) 2009-10-19 2009-10-19 Treatment using reprogrammed mature adult cells

Publications (1)

Publication Number Publication Date
TN2012000157A1 true TN2012000157A1 (en) 2013-12-12

Family

ID=42199514

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000157A TN2012000157A1 (en) 2009-10-19 2012-04-04 Treatment using reprogrammed mature adult cells

Country Status (17)

Country Link
EP (1) EP2490702A1 (en)
JP (1) JP6073135B2 (en)
KR (1) KR101766203B1 (en)
CN (1) CN102647989A (en)
AU (1) AU2009354350B2 (en)
CA (1) CA2781522A1 (en)
CH (1) CH704227B1 (en)
CU (1) CU24006B1 (en)
IL (1) IL218902A (en)
MA (1) MA33740B1 (en)
MX (1) MX2012004522A (en)
PH (1) PH12012500714A1 (en)
RU (1) RU2635317C2 (en)
TN (1) TN2012000157A1 (en)
UA (1) UA109265C2 (en)
WO (1) WO2011048350A1 (en)
ZA (1) ZA201202664B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170296595A1 (en) 2014-09-18 2017-10-19 North Carolina State University Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof
JP6113133B2 (en) 2014-11-06 2017-04-12 日本メナード化粧品株式会社 Stem cell undifferentiated state maintenance agent and growth promoter
WO2017066760A1 (en) 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
CN107114355A (en) * 2016-08-01 2017-09-01 北京世纪劲得生物技术有限公司 A kind of fat cell protection liquid and preparation method thereof
EP3589291A4 (en) * 2017-02-28 2020-11-25 Vor Biopharma, Inc. COMPOSITIONS AND METHODS OF INHIBITION OF CELL LINE SPECIFIC PROTEINS
CN109731012A (en) * 2017-10-30 2019-05-10 邹兆中 It improves biological immune and treats the active method of active principle
CN109706119B (en) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 Culture system and method for expanding hematopoietic stem cells and application thereof
MX2021002415A (en) 2018-08-28 2021-09-21 Vor Biopharma Inc Genetically engineered hematopoietic stem cells and uses thereof.
KR20200025210A (en) * 2018-08-29 2020-03-10 주식회사 스템모어 Composition for culturing dermal papilla cells and the method for culturing dermal papilla cells using the same
WO2021240204A1 (en) * 2020-05-23 2021-12-02 Pakravan Nafiseh Sperm head for resolution of inflammation, tissue repair & regeneration, and restoration of tissue function: new approach of cell therapy
CN114231481B (en) * 2021-12-21 2023-07-18 中国人民解放军总医院 A chemical induction method for reprogramming dermal fibroblasts into endothelial progenitor cells
WO2023217125A1 (en) * 2022-05-10 2023-11-16 上海赛立维生物科技有限公司 Prostate precursor-like cell and cell preparation, preparation method therefor and use thereof
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells
WO2025143018A1 (en) * 2023-12-28 2025-07-03 サントリーホールディングス株式会社 Composition for suppressing decline in curiosity or improving curiosity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US7112440B2 (en) * 1995-02-02 2006-09-26 Ghazi Jaswinder Dhoot Method of increasing the relative number of CD45 low cells in a cell population
US9068164B1 (en) * 1995-02-02 2015-06-30 Tristem Trading (Cyprus) Limited Method of preparing an undifferentiated cell
EP0769203B1 (en) * 1995-05-02 1999-08-18 Koninklijke Philips Electronics N.V. Colour cathode ray tube
US20050037490A1 (en) * 1999-10-29 2005-02-17 Lawrence Rosenberg Medium for preparing dedifferentiated cells
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
WO2006014642A1 (en) * 2004-07-22 2006-02-09 Five Prime Therapeutics, Inc. Method of producing autologous embryonic stem cells
US20120128655A1 (en) * 2009-04-03 2012-05-24 The Mclean Hospital Corporation Induced pluripotent stem cells

Also Published As

Publication number Publication date
EP2490702A1 (en) 2012-08-29
RU2635317C2 (en) 2017-11-10
UA109265C2 (en) 2015-08-10
JP2013508343A (en) 2013-03-07
JP6073135B2 (en) 2017-02-01
MX2012004522A (en) 2012-05-08
CN102647989A (en) 2012-08-22
CA2781522A1 (en) 2011-04-28
WO2011048350A1 (en) 2011-04-28
AU2009354350A1 (en) 2012-04-19
CU24006B1 (en) 2014-06-27
PH12012500714A1 (en) 2012-10-29
AU2009354350B2 (en) 2015-09-03
KR101766203B1 (en) 2017-08-08
CH704227B1 (en) 2015-05-15
MA33740B1 (en) 2012-11-01
RU2012120713A (en) 2013-11-27
IL218902A (en) 2017-06-29
ZA201202664B (en) 2013-02-27
IL218902A0 (en) 2012-06-28
CU20120063A7 (en) 2012-10-15
KR20120099686A (en) 2012-09-11

Similar Documents

Publication Publication Date Title
TN2012000157A1 (en) Treatment using reprogrammed mature adult cells
Salgado et al. Tissue engineering and regenerative medicine: past, present, and future
IL260117A (en) Treatment of diseases, disorders or conditions of the lung using placental cells
MX2019005130A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin.
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
MX2011009751A (en) Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
WO2007131232A8 (en) Compositions and their uses directed to ptpr alpha
MX2013002381A (en) Bone marrow derived cd271 precursor cells for cardiac repair.
EP2703481A4 (en) BROWN ADIPOCYTES DERIVED FROM PLURIPOTENT STEM CELLS, CELL AGGREGATE DERIVED FROM PLURIPOTENT STEM CELLS, PROCESS FOR THEIR PRODUCTION, CELL THERAPY AND MEDICAL THERAPY THEREFOR
CA2904533C (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
NZ607195A (en) Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2013078376A3 (en) Isoxazole treatments for diabetes
PH12014500739B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
MY157168A (en) Treatment using reprogrammed mature adult cells
WO2012177565A3 (en) Regulation of macrophage activation using mir - 125b
AR073910A1 (en) TREATMENT OF DIFFERENT DISEASES, USING REPROGRAMED MATURE ADULT CELLS.
UY32186A (en) TREATMENT USING REPROGRAMED MATURE ADULT CELLS
TR201204532T1 (en) Treatment using re-programmed mature adult cells.
TH125509A (en) Treatment that uses reprogrammed mature adult cells
WO2010110602A3 (en) Method for regenerating dopaminergic neurons in the substantia nigra pars compacta using human adult stem cells or precursor cells
RU2007100519A (en) METHOD FOR TREATING COSOGLASION IN CHILDREN
UA49781U (en) METHOD FOR treatment of bronchial asthma at children in acute period
MX2010008103A (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib.
UA52233U (en) method for treatment of funal keratites
Montes-Worboys et al. B61 POTPOURRI OF INJ-OURRI: EPITHELIAL CELLS IN LUNG INJURY AND REPAIR: Pro-Fibrotic Tenascin-C Synthesis Of Human Alveolar Epithelial Cells And Lung Fibroblasts Is Modulated By Tgf-[Beta] And Pirfenidone Treatment